Edition:
United States

Palatin Technologies Inc (PTN.A)

PTN.A on American Stock Exchange

0.57USD
2 Dec 2016
Change (% chg)

$0.01 (+2.57%)
Prev Close
$0.56
Open
$0.59
Day's High
$0.59
Day's Low
$0.57
Volume
266,256
Avg. Vol
186,687
52-wk High
$0.89
52-wk Low
$0.40

PTN.A

Chart for PTN.A

About

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and... (more)

Overall

Beta: 1.56
Market Cap(Mil.): $57.26
Shares Outstanding(Mil.): 108.04
Dividend: --
Yield (%): --

Financials

  PTN.A Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -0.33 -- --
ROI: -349.09 -1.09 14.95
ROE: -- -2.39 16.29

BRIEF-Palatin Technologies, Inc. reports first quarter 2017 results

* There were no revenues recorded in quarters ended september 30, 2016 and 2015

Nov 15 2016

Exclusive: Female Viagra contender Palatin Technologies explores potential sale - source

Palatin Technologies Inc , which is looking to take the throne from Addyi as the primary drug treatment for low sex drive in women, has hired an investment bank to explore a sale or licensing deal, according to a source familiar with the matter.

Nov 02 2016

BRIEF-Bremelanotide meets co-primary endpoints in advanced trials for hypoactive sexual desire disorder

* Palatin Technologies Inc - new drug application (nda) to FDA targeted for second half of 2017 for Bremelanotide

Nov 01 2016

Palatin female sexual desire drug succeeds in trials; shares soar

A drug meant to boost the libido of pre-menopausal women distressed by lack of sexual desire met the main goals of a pair of late stage clinical trials, according to initial results released on Tuesday by its developer, Palatin Technologies Inc , and its shares rose 66 percent.

Nov 01 2016

BRIEF-Palatin Technologies announces topline results for phase 3 trials with Bremelanotide

* Topline results for phase 3 trials with Bremelanotide for HSDD (Hypoactive Sexual Desire Disorder)are projected to be released early Q4 of calendar year 2016 Source text for Eikon: Further company coverage:

Sep 23 2016

BRIEF-Palatin Technologies reports Q4 loss $0.09/shr

* Palatin Technologies, Inc. reports fourth quarter and fiscal year 2016 results

Sep 20 2016

BRIEF-Palatin Technologies entered commercial supply agreement with unit of Catalent Pharma solutions

* On june 20, 2016 co entered commercial supply agreement with unit of catalent pharma solutions with an effective date of june 10

Jun 23 2016

Earnings vs. Estimates